RxDoctor Payments Data

Benjamin Havemann, MD

Gastroenterology · Austin, TXNPI 1154347870

Payments from drug & device makers

$26,837in general payments, 2019–2025

Across 522 payments — averaging $51.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$9K
  • Ferring Pharmaceuticals Inc.$7K
  • AbbVie$3K
  • Bristol Myers Squibb$2K
  • Janssen Scientific Affairs, LLC$859
  • Pfizer$733
  • plus $4K from 28 others

What the payments were for

  • Consulting fees$6002%
  • Speaking & faculty fees$14,48554%
  • Travel & lodging$6312%
  • Food & beverage$10,50139%
  • Education$6212%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$26,837 in reported general payments places this provider in the 80th percentile of 1,350 gastroenterology providers in Texas.

See all gastroenterology providers in Texas

Medicare billing

Part B allowed, 2024
$147,300
Medicare patients
604
Services billed
1,111

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RinvoqUpadacitinib18$164,428
CreonLipase/Protease/Amylase16$53,192
LinzessLinaclotide24$15,723
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates104$6,606
Lubiprostone26$5,766
PlenvuPeg3350/Sod Sul/Nacl/Kcl/Asb/C38$5,144
Dexlansoprazole DrDexlansoprazole20$4,881
Mesalamine20$4,565
Pantoprazole Sodium283$3,858
Balsalazide Disodium38$3,605
Mesalamine ErMesalamine11$1,797
Famotidine23$1,773
Budesonide DrBudesonide20$1,320
Omeprazole91$1,215
Azathioprine18$1,187

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRinvoq, Creon, Linzess$3,394$233,34358 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCPlenvu$534$5,14438 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,350 gastroenterology providers in Texas.

Other gastroenterology in Austin

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →